Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies


1Experimental Rheumatology Unit, Department of Medicine (Solna), Karolinska Institutet, Stockholm, Sweden. 1Rheumatology Unit, and Experimental Endocrinology, Department of Medicine (Solna), Karolinska Institutet, Stockholm, Sweden. 3Children’s National Medical Center, National Institutes of Health, Bethesda, Maryland, USA. 4Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 5Unit of Biostatistics, Institute of Environmental Medicine, 6Department of Laboratory Medicine, and 7Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden. 8Department of Clinical and Experimental Medicine, Division of Neurology, Faculty of Health Sciences, Linköping University, Linköping, Sweden. 9Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic. 10Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden. 11Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic. 12Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden. 13Experimental Rheumatology Unit, Department of Medicine (Solna), Karolinska Institutet, Stockholm, Sweden.

Mutations of the gene encoding four-and-a-half LIM domain 1 (FHL1) are the causative factor of several X-linked hereditary myopathies that are collectively termed FHL1-related myopathies. These disorders are characterized by severe muscle dysfunction and damage. Here, we have shown that patients with idiopathic inflammatory myopathies (IIMs) develop autoimmunity to FHL1, which is a muscle-specific protein. Anti-FHL1 autoantibodies were detected in 25% of IIM patients, while patients with other autoimmune diseases or muscular dystrophies were largely anti-FHL1 negative. Anti-FHL1 reactivity was predictive for muscle atrophy, dysphagia, pronounced muscle fiber damage, and vasculitis. FHL1 showed an altered expression pattern, with focal accumulation in the muscle fibers of autoantibody-positive patients compared with a homogeneous expression in anti-FHL1-negative patients and healthy controls. We determined that FHL1 is a target of the cytotoxic protease granzyme B, indicating that the generation of FHL1 fragments may initiate FHL1 autoimmunity. Moreover, immunization of myositis-prone mice with FHL1 aggravated muscle weakness and increased mortality, suggesting a direct link between anti-FHL1 responses and muscle damage. Together, our findings provide evidence that FHL1 may be involved in the pathogenesis not only of genetic FHL1-related myopathies but also of autoimmune IIM. Importantly, these results indicate that anti-FHL1 autoantibodies in peripheral blood have promising potential as a biomarker to identify a subset of severe IIM.

Introduction

Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of rare systemic autoimmune diseases collectively called myositis, which causes progressive muscle weakness. Several forms of the disease, including polymyositis (PM), dermatomyositis (DM), inclusion body myositis (IBM), and immune-mediated necrotizing myopathy can be distinguished on the basis of clinical features, muscle histopathology, and autoantibody profiles (1-4). For IBM, muscle-specific autoantibodies against cytosolic 5'-nucleotidase 1A (cN-1A) (5-7) and desmin (8) were recently described as serological biomarkers for this disease subtype. Interestingly, myositis-specific autoantibodies described in PM and DM are directed against ubiquitously expressed intracellular proteins (9-11) and show a lack of muscle specificity. Identification of novel muscle-specific targets involved in immune-mediated processes and their detailed characterization will facilitate the understanding of the initiation and perpetuation of chronic autoimmune attacks on the skeletal muscle.

FHL1 proteins are characterized by four-and-a-half highly conserved LIM domains, which mediate protein-protein interactions. FHL1 is predominantly expressed in the skeletal muscle, and, although its precise function is not known, there is experimental evidence showing that FHL1 is involved in muscle growth (12), differentiation (13, 14), and structural maintenance such as sarcromere assembly (15). FHL1 is further described to be involved in cell signaling pathways including Smad/TGF-β-like- (16), estrogen- (17), Notch- (18), and MAPK (19) cascades. Several spliced variants of FHL1 have been identified as containing additional domains with different localization patterns and tentatively coding for protein variants with different functions (20). Importantly, genetic FHL1 mutations are causative for various rare X-linked myopathies that mostly appear in youth; these include reducing body myopathy (RBm) (21-24), X-linked myopathy characterized by postural muscle atrophy (XMPMA) (25, 26), scapuloperoneal myopathy (SPM) (27), and Emery-Dreifuss muscular dystrophy (EDMD) (28). These FHL1-associated myopathies share pathological features, i.e., severe muscular dysfunction and damage, but
Anti-FHL1 autoantibodies were identified using a muscle-specific cDNA library. In order to identify genes encoding putative muscle-specific autoantigens, we screened a muscle cDNA library with sera from 3 representative patients with established IIM, 1 with classical DM (patient A), 1 with cancer-associated DM (patient B), and 1 with PM and anti–histidyl-tRNA synthetase (Jo-1) antibodies (patient C) (Supplemental Table 1; supplemental material available online with this article; doi:10.1172/JCI81031DS1). In the serum from the Jo-1+ patient, we identified several clones with cDNA inserts of the histidyl-tRNA synthetase, qualifying it as a good internal control for the methodology used. 35 of the anti-FHL1+ patients were analyzed (lanes 1–35). Lanes show reactivity of sera from anti-FHL1+ patients 10 and 29 to MaBP loaded next to FHL1-MaBP, of sera from 4 HCs (sera 3* with positive reactivity detected by ELISA in B), of sera from a positive control (PC) using a commercial anti-FHL1 antibody, and of sera from 3 anti-FHL1+ patients. Reactivity to FHL1 in sera from HCs and IIM patients was compared by ELISA with anti-FHL1 reactivity in sera from patients with MCTD (n = 19), RA (n = 67), pSS (n = 35), SLE (n = 33), and SSc (n = 32), as well as in sera from patients with neuromuscular disease (NMD; n = 9). Statistical analysis for A–C was performed using a 2-tailed Mann Whitney U test; each data point represents 1 individual, and horizontal bars indicate the mean values. For A, B, and E, normalized A405 values (norm. A405 = FHL1-MaBP-A405 minus MaBP-A405) are shown.

Figure 1. IIM patients have anti-FHL1 autoantibodies that are specific to this disease. (A) Sera from patients with IIM (PM, DM, or IBM; n = 141) were analyzed by ELISA for reactivity to recombinant FHL1-MaBP fusion protein and compared with sera from sex- and age-matched HCs (n = 126). (B) A cutoff value was calculated, allowing subdivision of the patients into anti-FHL1+ (aFHL1+) and anti-FHL1− patients (cutoff = mean [norm. absorbance HC] + 2 × SD = 0.26228). (C) Anti-FHL1 positivity was confirmed by another ELISA using recombinant His-tagged FHL1 and by comparing anti-FHL1+ (n = 35) with sex- and age-matched anti-FHL1− patients (n = 30) as well as by Western blotting (D) using recombinant FHL1-MaBP fusion protein. All 35 of the anti-FHL1+ patients were analyzed (lanes 1–35). Lanes show reactivity of sera from anti-FHL1+ patients 10 and 29 to MaBP loaded next to FHL1-MaBP, of sera from 4 HCs (sera 3* with positive reactivity detected by ELISA in B), of sera from a positive control (PC) using a commercial anti-FHL1 antibody, and of sera from 3 anti-FHL1− patients. (E) Reactivity to FHL1 in sera from HCs and IIM patients was compared by ELISA with anti-FHL1 reactivity in sera from patients with MCTD (n = 19), RA (n = 67), pSS (n = 35), SLE (n = 33), and SSc (n = 32), as well as in sera from patients with neuromuscular disease (NMD; n = 9). Statistical analysis for A–C was performed using a 2-tailed Mann Whitney U test; each data point represents 1 individual, and horizontal bars indicate the mean values. For A, B, and E, normalized A405 values (norm. A405 = FHL1-MaBP-A405 minus MaBP-A405) are shown.

Results

Anti-FHL1 autoantibodies were identified using a muscle-specific cDNA library. In order to identify genes encoding putative muscle-specific autoantigens, we screened a muscle cDNA library with sera from 3 representative patients with established IIM, 1 with classical DM (patient A), 1 with cancer-associated DM (patient B), and 1 with PM and anti–histidyl-tRNA synthetase (Jo-1) antibodies (patient C) (Supplemental Table 1; supplemental material available online with this article; doi:10.1172/JCI81031DS1). In the serum from the Jo-1+ patient, we identified several clones with cDNA inserts of the histidyl-tRNA synthetase, qualifying it as a good internal control for the methodology used. In 2 of the 3 tested sera (from patients A and B), we identified clones that had an 843-bp ORF and a predicted amino acid sequence of 281 residues with 100% identity with FHL1. As FHL1 missense mutations have been linked to congenital myopathies in earlier studies (23, 26, 28, 30), it was selected for further analysis.
FHL1 autoantibodies are specific to inflammatory myopathies. Using an ELISA able to detect IgG antibodies against FHL1 protein, we investigated sera from 141 patients with IIM, from 126 sex- and age-matched healthy controls (HCs), and from a total of 195 patients with other autoimmune diseases or neuromuscular disease (NMD). We used FHL1 coupled to maltose-binding protein (MaBP) as an antigen and MaBP alone as a control. The latter showed either no or occasional reactivity, thereby demonstrating the specificity of the FHL1 ELISA. Patients with IIM showed significantly higher levels of anti-FHL1 autoantibodies compared with levels in healthy individuals (Figure 1A, $P < 0.0001$). Examination of HCs allowed the calculation of a cutoff value by which anti-FHL1- and anti-FHL1+ patients could be differentiated. Thus, 35 of 141 patients (24.8%) were identified as positive for anti-FHL1 autoantibodies (Figure 1B). Of note, the cDNA library screen showing positivity for anti-FHL1 autoantibodies in patients A and B and negativity for these autoantibodies in patient C was confirmed by ELISA, indicating the reliability of these different methodologies. Dilutional linearity was demonstrated by serial dilution ELISA experiments on anti-FHL1- and anti-FHL1+ sera as well as on HC sera and allowed detection of the optimal dilution factor (Supplemental Figure 1). Anti-FHL1 positivity was subsequently confirmed by another ELISA using a recombinant His-tagged FHL1 protein (Figure 1C) and by Western blotting using an FHL1-MaBP fusion protein (Figure 1D). Western blotting also verified the absence of anti-FHL1 reactivity in HC sera and no reactivity of anti-FHL1+ sera to the MaBP protein (Figure 1D). In addition, to show reactivity of anti-FHL1+ sera to the native autoantigen, we applied sera to normal muscle tissue sections and performed immunofluorescence and confocal microscopy. As shown in Supplemental Figure 2A, staining with anti-FHL1+ sera yielded a diffuse, homogenous cytoplasmic staining of muscle fibers of normal human muscle tissue, whereas no staining of muscle fibers was observed using HC or anti-FHL1– sera. Moreover, the staining observed upon incubation with anti-FHL1+ sera could be blocked by preincubating the serum with recombinant FHL1-MaBP protein (Supplemental Figure 2B), demonstrating reactivity of the antibodies to the native FHL1 protein in muscle fibers. The presence of anti-FHL1 autoantibodies was subsequently confirmed in an independent cohort of patients with IIM from the Czech Republic; here, 31 of 129 patients (24%) were identified as anti-FHL1+ (Supplemental Figure 3).

Figure 2. The presence of anti-FHL1 autoantibodies is associated with pronounced muscle damage. (A) Statistical analysis revealed that anti-FHL1 positivity was associated with dysphagia ($P = 0.002$, Fisher’s exact test), distal muscle weakness ($P = 0.022$, Fisher’s exact test), clinical atrophy ($P = 0.007$, Fisher’s exact test), fiber necrosis ($P = 0.042$, Fisher’s exact test), and connective tissue/fat replacement ($P = 0.002$, Fisher’s exact test). (B) Clinical disease severity score for anti-FHL1+ compared with anti-FHL1– IIM patients. Scoring for disease severity was done by examining disease outcome determined at the patient’s last clinic visit. (C) H&E- and Gomori trichrome–stained muscle tissue sections of 20 patients with anti-FHL1 autoantibodies were examined for histopathology and compared with stained muscle tissue sections from sex-, age-, and diagnosis-matched (PM, DM, and IBM; $n = 13$) anti-FHL1+ patients. Scoring was done using a 0–10 cm VAS. (D) Representative H&E-stained images of muscle tissue from 2 anti-FHL1+ patients with low histopathological VAS scores (patients 1 and 2); 1 anti-FHL1+ patient with a medium VAS score (patient 3); and 3 anti-FHL1+ patients with high VAS scores (patients 4, 5, and 6). Images show inflammatory infiltrates, connective tissue/fat replacement (indicated by asterisks), internal nuclei (indicated by arrows), and massive fiber size variation. Scoring in B and C was done blindly with regard to anti-FHL1 autoantibody status. Statistics for B and C were calculated by 2-tailed Mann-Whitney $U$ test; each data point represents 1 individual, and horizontal bars indicate the mean values.
ELISA results yielded a 25% sensitivity, a 97% specificity, and an 80% positive predictive value for diagnosing myositis using anti-FHL1 autoantibodies.

In addition, in patients with noninflammatory NMD with muscle weakness, we could not detect any anti-FHL1 reactivity (Figure 1E), indicating that the autoantibodies are not formed merely as a consequence of excessive destruction of muscle tissue.

The HLA DRB1*03/*13 genotype is more frequent in anti-FHL1+ patients. To elucidate a potential immunogenetic contribution, we compared the frequency of HLA-DRB1 haplotypes in anti-FHL1+ and anti-FHL1– patients. We found that the combination of HLA-DRB1*03/*13 haplotypes was more frequent in anti-FHL1+ patients than in anti-FHL1– patients; 7 of 33 anti-FHL1+ patients (21.2%) were found to have this genotype compared to 0 of 34 anti-FHL1– patients (0%). Logistic regression analyses confirmed that anti-FHL1 autoantibodies are highly myositis specific: odds ratio (OR) = 14.1 (95% CI 4.2–47.6, P < 0.0001) for IIM; OR = 1.9 (95% CI 0.19–19.4, P = 0.586) for MCTD; OR = 0.54 (95% CI 0.05–5.3, P = 0.594) for RA; OR = 2.3 (95% CI 0.37–14.7, P = 0.368) for SSc; and OR = 1.1 (95% CI 0.11–11.2, P = 0.923) for pSS, when adjusting for age and sex and using HCs as a reference. The
a scoring system with a focus on muscle involvement determined at the patient’s most recent medical examination. Anti-FHL1+ patients had a worse clinical outcome score compared with that for anti-FHL1– patients, and patients with the worst possible disease score were found in the anti-FHL1+ group (Figure 2B). These patients were characterized by a high degree of muscle weakness or complete loss of ambulation and a remarkably progressive and therapy-resistant disease history.

We also found significant associations between the presence of anti-FHL1 autoantibodies and muscle biopsy features including fiber necrosis ($P = 0.042$) and connective tissue replacement of muscle tissue ($P = 0.002$), as evidenced by examination of the first available muscle biopsy specimen (Figure 2A and Supplemental Table 4). The observed association with distinct muscle biopsy features in anti-FHL1+ patients was further supported when all available H&E- and Gomori trichrome–stained muscle tissue sections from 20 anti-FHL1+ patients and 13 sex-matched, age-matched, and diagnosis-matched (PM, DM, and IBM) anti-FHL1– patients were scored for severity according to a visual analog scale (VAS).

Anti-FHL1 autoantibodies are associated with severe muscle pathology. Long-term clinical follow-up data were available for 132 of 141 (94%) patients with IIM (anti-FHL1+, $n = 33$; anti-FHL1–, $n = 99$) (Supplemental Table 3). FHL1 autoantibodies were detectable in all 3 IIM subtypes; 19 of 33 anti-FHL1+ patients were diagnosed with PM (58%), 10 with DM (30%), 1 with juvenile DM (3%), and 3 of 33 patients with IBM (9%), reflecting the frequencies of the subtypes in the investigated myositis cohort (see Supplemental Table 3). Anti-FHL1+ patients developed dysphagia more often than did anti-FHL1– patients (28 of 33 [85%] anti-FHL1+ compared with 52 of 96 [54%] anti-FHL1– patients, $P = 0.002$) (Figure 2B and Supplemental Table 4).

To further examine the associations between the presence of anti-FHL1 autoantibodies and clinical muscle pathology, we developed a scoring system with a focus on muscle involvement determined at the patient’s most recent medical examination. Anti-FHL1+ patients had a worse clinical outcome score compared with that for anti-FHL1– patients, and patients with the worst possible disease score were found in the anti-FHL1+ group (Figure 2B). These patients were characterized by a high degree of muscle weakness or complete loss of ambulation and a remarkably progressive and therapy-resistant disease history.

We also found significant associations between the presence of anti-FHL1 autoantibodies and muscle biopsy features including fiber necrosis ($P = 0.042$) and connective tissue replacement of muscle tissue ($P = 0.002$), as evidenced by examination of the first available muscle biopsy specimen (Figure 2A and Supplemental Table 4). The observed association with distinct muscle biopsy features in anti-FHL1+ patients was further supported when all available H&E- and Gomori trichrome–stained muscle tissue sections from 20 anti-FHL1+ patients and 13 sex-matched, age-matched, and diagnosis-matched (PM, DM, and IBM) anti-FHL1– patients were scored for severity according to a visual analog scale (VAS).
Patients with autoantibodies against FHL1 had a mean muscle biopsy severity VAS score of 2.8 cm, whereas anti-FHL1 patients had a VAS score of 0.9 cm (Figure 2C). As shown in the representative tissue sections in Figure 2D, anti-FHL1 patients with high VAS scores, as compared with anti-FHL1 patients with low VAS scores and an anti-FHL1 patient with a medium VAS score, had more connective tissue and fat replacement (Figure 2D, asterisks), internal nuclei (Figure 2D, arrows), variation of fiber size, and more frequently pronounced inflammatory infiltrates. The overall histopathology score also revealed that patients with the highest possible VAS score (over 6.0 cm) were found in the anti-FHL1+ group, further confirming a severe muscle histopathology.

To further test the stability of the anti-FHL1 autoantibody response and its sensitivity to treatment over time in either severely affected patients or patients with mild disease, we performed ELISAs on longitudinal serum samples from representative patients (Supplemental Figure 5). For the analyzed patients with progressive disease refractory to therapeutic intervention and characterized by a poor outcome score (determined in Figure 2B), anti-FHL1 autoantibody levels were constantly above the cutoff levels of healthy individuals (Supplemental Figure 5A). Selected patients with good response to therapy were anti-FHL1+ only occasionally (Supplemental Figure 5B), and anti-FHL1 patients appeared negative over the entire analysis period (Supplemental Figure 5C). We could not detect any general influence of treatment on serum levels of anti-FHL1 autoantibodies, and anti-FHL1 autoantibody levels did not correlate with variations in serum levels of creatine kinase (CK) (Supplemental Table 5).

We found no associations between anti-FHL1 autoantibodies and any of the laboratory measurements (Supplemental Table 5), nor did we detect the presence of other autoantibodies including the muscle-specific autoantibody cN-1A (ref. 7 and Supplemental Table 6). Our analysis of the distribution of the P values reported in Supplemental Tables 4 and 5 revealed a proportion of less than 10% of low P values that was significantly higher (P < 0.0001) than what would be expected by chance (Supplemental Figure 6). These associations indicate a link between positivity for anti-FHL1 autoantibodies and disease severity, particularly that affecting skeletal muscle.

FHL1 shows an altered expression pattern in muscles of anti-FHL1+ patients. To gain insights into mechanisms of muscle damage related to anti-FHL1+ inflammatory myopathies, we used immunofluorescence staining with a commercial anti-FHL1 antibody and confocal microscopy to examine FHL1 protein expression in muscle tissue from patients with anti-FHL1+ myositis compared with that from healthy individuals and anti-FHL1 patients. Healthy muscle tissue (Figure 3, left 2 panels) and muscle tissue from anti-FHL1+ patients (Figure 3, bottom panels) showed a homogenous expression pattern of FHL1 that was mainly sarcoplasmic and distributed uniformly along the muscle fiber. In patients with anti-FHL1+ myositis, the pattern was strikingly different; some fibers had focal accumulations of FHL1, whereas others had almost no FHL1 expression (Figure 3, right 2 panels). In addition, we observed colocalization of FHL1 with laminin in the sarcolemma, which was less obvious in muscle tissue from HCs. Specificity of the staining was confirmed by using appropriate isotype controls (Supplemental Figure 7A) and by blocking FHL1 staining with recombinant FHL1 (Supplemental Figure 7B).

As FHL1 can undergo alternative splicing and different isoforms have been described (20), we performed mRNA expression analysis of the 3 major FHL1 isoforms (isoforms A, B, and C). All 3 isoforms were expressed similarly in HC, anti-FHL1+ muscle tissue lysates (Figure 4A), with a tendency toward lower expression levels of isoform A in anti-FHL1+ versus anti-FHL1 lysates. To investigate whether FHL1 mRNA expression is reflected by protein expression, we performed Western blot analysis of muscle tissue lysates. In HC muscle tissue lysates, 1 major band at around 38 kDa was detected (Figure 4B). In contrast, Western blot analysis of muscle tissue lysates from anti-FHL1+ patients showed strong expression of 2 additional bands at 34 and 25 kDa (Figure 4B). All 3 bands contained FHL1.
as shown by gel extraction and subsequent mass spectrometric analysis (Supplemental Figure 8). Quantification of intensity and normalization to the housekeeping gene GAPDH for these 3 bands revealed that expression of the 38-kDa band was comparable between muscle lysates from HCs and from patients with myositis, with a tendency toward lower expression in anti-FHL1+ versus anti-FHL1– patients (Figure 4C). In contrast, expression intensity of the 34- and 25-kDa bands consistently increased in muscle tissue lysates from both HCs and anti-FHL1– patients and reached a maximum in muscle tissue lysates from anti-FHL1+ patients (Figure 4C).

Thus, muscle tissue lysates from anti-FHL1+ patients showed a distinct protein expression pattern, as demonstrated by both immunofluorescence confocal microscopy and Western blot analysis, suggesting that the protein might be subject to degradation in a subset of patients with myositis and that this degradation is most pronounced in anti-FHL1+ patients.

FHL1 is susceptible to cleavage by granzyme B. Cleavage of auto-antigens mediated by the cytotoxic protease granzyme B is a frequent feature of systemic autoimmune diseases and is believed to contribute to the initiation and propagation of autoimmunity (32). We therefore addressed the question of whether endogenous FHL1 might be cleaved by granzyme B by performing in vitro cleavage assays with human skeletal muscle cell lysates. Indeed, we observed a dose-dependent fragmentation of FHL1 in the presence of increasing concentrations of granzyme B (Figure 5A). To eliminate the role of endogenous muscle caspases in the cleavage of FHL1, we used different inhibitors to inactivate caspase activity in the muscle lysate. Interestingly, the presence of z-VAD and z-DEVD could not prevent granzyme B–mediated cleavage of FHL1 (Figure 5B), demonstrating that muscle FHL1 is a direct substrate of granzyme B, with a resulting cleavage fragment of 30 kDa. Direct cleavage of FHL1 by granzyme B was further confirmed using recombinant proteins; all proteins tested,
including His-tagged FHL1 (Figure 5C), commercially available recombinant FHL1 (Figure 5D), and FHL1-MaBP fusion protein (Figure 5E), were cleaved, and the 30-kDa cleavage fragment was detected. As this fragment was detectable with both an antibody binding to the N-terminus and another antibody binding to the C-terminus of the protein (under the conditions used in Figure 5E), we concluded that the cleavage site is located in the N-terminal portion (Figure 5E, scheme). Tetrapeptide substrate specificity of human granzyme B has been determined previously (33, 34). This specificity and the fragment sizes generated by granzyme B cleavage were used to predict that the cleavage site in FHL1 is the tetrapeptide IGAD with P1 aspartic acid at amino acid position 50 (Figure 5F). The identified cleavage site was confirmed by site-directed mutagenesis of the relevant P1 aspartic acid to alanine (D$_{50} \rightarrow$ A$_{50}$), leading to resistance of FHL1 protein to cleavage by granzyme B (Figure 5G).

Anti-FHL1 immunity in MHC class I transgenic mice aggravates muscle weakness. To further analyze the role of FHL1 in IIM pathogenesis, we used an IIM mouse model. As previously demonstrated, upregulation of MHC class I in skeletal muscle causes muscle inflammation and weakness in double-transgenic mice (referred to herein as HT mice), whereas single-transgenic littermates (referred to herein as H mice) do not develop IIM symptoms (35). To study the impact of an immune response formed against FHL1, we immunized myositis-susceptible HT and control H mice with either FHL1-MaBP protein or MaBP alone. Blood was collected at several time points after immunization (Figure 6A), and sera were analyzed by ELISA for FHL1 reactivity. We detected anti-FHL1 autoantibodies in both H and HT mice immunized with FHL1-MaBP (Figure 6B). H mice receiving FHL1 fusion protein or MaBP were unaffected during the experimental period. Nine weeks after immunization, we detected an increased weakness of forelimbs and hind limbs in both HT groups compared with the H mice. In addition, a more pronounced weakness was observed in the FHL1-immunized HT group compared with the MaBP control–immunized mice (Figure 6C). On average, the forelimbs of HT mice immunized with MaBP lost 15% of their grip strength compared with the healthy H mice, while FHL1-immunized HT mice lost 29% of their grip strength compared with the healthy H mice. For the hind limbs, grip strength was reduced by 13% in the MaBP-immunized HT mice compared with the H mice versus a 24% grip strength reduction observed in the FHL1-immunized HT mice (Figure 6C). BW measurement revealed no statistically significant difference in the MaBP control groups. However, weight loss in the group of FHL1-immunized HT mice was pronounced and statistically significantly increased compared with that of the FHL1-immunized H mice (Figure 6D). The survival rate for the FHL1-immunized HT group was 12.5% (1 of 8 mice in total survived until the end of the experiment), whereas the survival rate for the HT MaBP group was 50% (Figure 6E). The hazard ratio was determined to be 2.20, indicating that mice in the HT FHL1-MaBP group died at 2.2 times the rate of mice in the control HT MaBP group for the same time period.

As expected, FHL1-immunized HT mice showed prominent muscle cell damage, demonstrated by IgM depositions in muscle tissue (Figure 6F). In addition, we observed increased expression levels of Cd4 and Cd8a as well as Gzmb and Prf1 in the hind-limb muscle tissue of FHL1-immunized HT mice (Figure 6G), indicating the presence of T cell infiltrates.

Discussion

Our study identifies what we believe to be a novel and muscle-specific autoantigen, FHL1, in a subset of IIM patients characterized by severe skeletal muscle involvement. Strikingly, mutations of the encoding FHL1 gene are associated with severe inherited myopathy (23, 26, 28, 30). Immunization of myositis-prone mice with FHL1 aggravated muscle weakness and caused increased mortality. Together, these data suggest that we have identified a new variant of severe myopathy characterized by the presence of anti-FHL1 autoantibodies that may represent a new prognostic biomarker for this disease variant.

Our current approach using a muscle-specific expression library for detecting new muscle-specific autoantigens has not, to our knowledge, been used previously to identify autoantibody targets in IIM. The present study showing that the FHL1 antigen is a muscle-specific target in IIM therefore illustrates the power of this method and suggests that its application may identify additional autoantigens.

Which factors could account for FHL1 becoming an autoantigen that consequently drives the development of anti-FHL1 autoantibodies? Multiple studies have demonstrated that the majority of autoantigens targeted in systemic autoimmune diseases are substrates of granzymes, in particular granzyme B (32, 36–40), a serine protease found in the cytoplasmic granules of cytotoxic T lymphocytes and NK cells. Granzyme B–mediated cleavage of autoantigens can lead to the generation of neo-epitopes and thus promote initiation of immune responses (32). It can also influence protein function as well as redistribution within the cell (36, 37, 40, 41). Our finding that FHL1 is a target of granzyme B in vitro suggests a scenario that may also be operating in vivo in this subset of myositis and could explain the lower-molecular-weight fragments of FHL1 in the muscle detected by Western blotting (bands migrated at 34 and 25 kDa). Thus, susceptibility to granzyme cleavage could drive the exposure of novel FHL1 epitopes and lead to a subsequent break of tolerance and initiation of autoimmunity (Supplemental Figure 9). Here, 2 scenarios are possible: (a) cleavage of FHL1 might be a primary event during tissue damage, triggering a secondary immunity to FHL1, or (b) antibodies might first be generated against intact or cleaved FHL1, and, consequently, anti-FHL1 immunity becomes a driving feature and initiating event of this subset of IIM. We cannot at present distinguish between these 2 possibilities since we do not have access to the necessary pre-disease sera. However, considering the results of our longitudinal serum samples from patients with progressive disease, we can conclude that immunity to FHL1 appears at early time points of the disease and is characterized by remarkable stability and persistence, suggesting that it probably contributes to and aggravates IIM.

In addition, granzyme B cleavage or other mechanisms like posttranslational modifications, e.g., by oxidation (42), could induce instability of the secondary structure of FHL1 protein, similar to the events observed in genetic FHL1-related myopathies, which, consequently, might result in loss of protein functionality. Given the
The role of FHL1 as a critical modulator of muscle mass and strength enhancement (12), loss of FHL1 functionality could account for muscle degeneration and severe muscle pathology. Importantly, in muscle tissue of IIM patients with anti-FHL1 autoantibodies, FHL1 showed an altered expression pattern with focal accumulations. The pattern observed in anti-FHL1+ patients is remarkably similar to that caused by mutations of FHL1 in patients suffering from the genetic FHL1-related myopathy RBM, in which FHL1 appears to be progressively incorporated into intracytoplasmic inclusions (23).

The consequence of an autoimmune response to FHL1 for the pathogenesis of inflammatory myopathies was examined in IIM patients and in an MHC class I-dependent mouse model for myositis (35). In humans, the association between the presence of anti-FHL1 antibodies and myofiber damage is compatible with both a model in which immunity develops first and has secondary effects on muscle cells and a model in which neo-epitopes are primarily found in the muscle, and immunity occurs as a result of neo-epitope exposure and local activation of antigen-presenting cells. In addition, the HLA DRB1*03/*13 genotype was found to be more frequent in anti-FHL1+ patients, suggesting an involvement of classical MHC class II-dependent antigen presentation and CD4+ T cell help in the formation of anti-FHL1 autoantibodies. HLA alleles are known to be strongly associated with the development of myositis-specific antibodies, as demonstrated for different specificities (43–45), and a genome-wide association study in DM confirms the importance of HLA as a genetic contributor to IIM (46). The mouse experiment indicates that immunity to FHL1 may indeed contribute to IIM pathology, but so far only in mice that already have a mild form of the disease. This scenario is of course also possible in the human setting. In addition to autoantibodies detectable in the circulation, the animal model also revealed indications for T cell infiltrates present in the inflamed tissue that likely contribute to tissue injury and pathogenesis. Cytotoxic CD8+ T cells are of particular importance in IIM pathogenesis and were shown to be clonally expanded and to invade MHC class I-expressing muscle fibers (47–50). Whether anti-FHL1 autoantibodies themselves harbor pathogenic capacity and drive tissue destruction and fibrosis in addition to cell-mediated autoimmunity remains to be determined by future investigations.

Importantly, however, the newly identified anti-FHL1 antibodies may function as important biomarkers for a subset of severe inflammatory myopathy. Of particular interest in this context is the high frequency of patients with dysphagia, which has been previously described to be associated with high disease severity in IIM (51, 52), and an association with pronounced skeletal muscle damage.

In conclusion, we have identified and characterized what is, to our knowledge, a novel muscle-specific autoantigen in a subset of patients classified as having IIM with severe skeletal muscle involvement and a risk of poor prognosis. Thus, our study indicates a role of FHL1 in the pathogenesis of a subset of IIM, emphasizing the need for careful characterization of IIM disease subsets to improve our understanding of the molecular pathways. Further investigations of FHL1 and its corresponding autoantibodies in IIM may shed light on the possible mechanisms of development of autoimmunity in inflammatory muscle disease. In particular, a detailed characterization of the mechanisms that account for FHL1 becoming a central autoantigen in IIM in vivo, including the identification of antigenic FHL1 epitopes, is still needed. Another limitation is the small sample size in this study, in particular for the analysis of possible overrepresentations of a combination of HLA haplotypes. An extensive replication of the statistical analysis of the clinical parameters and genetic associations in a multicenter cohort will thus be an important future objective. Since FHL1 itself was described to positively modulate muscle growth and strength enhancement (12), a better understanding of the physiological and pathological functions associated with FHL1, its mutations, and autoimmunity may also lead to novel therapeutic approaches for inflammatory myopathies.

**Methods**

**Patients and clinical data.** For ELISAs, sera from patients with IIM (n = 141), followed at the Rheumatology Unit of Karolinska University Hospital, were compared with sera from sex- and age-matched HCs (n = 126), as well as sera from patients from the same clinic diagnosed with MCTD (n = 19), RA (n = 67), pSS (n = 35), SLE (n = 33), SSc (n = 32), and sera from patients with noninflammatory neuromuscular diseases (n = 9) followed at the Neurology Clinic of Linköping University Hospital in Linköping, Sweden (for RA, pSS, SLE, and SSc, patients were sex- and age-matched with anti-FHL1+ patients). The neuromuscular diseases represented different non-inflammatory, weakness-causing myopathies (3 patients with limb girdle muscular dystrophy [LGMD], 3 patients with myotonic dystrophy type 1 [DM1], 1 patient with congenital myasthenia, 1 patient with mitochondrial myopathy, and 1 patient with spinal muscular atrophy type 3 [SMA3]). The diagnoses were supported by muscle biopsies, electromyograms (EMGs), and the clinical features in each case. Hereditary myopathy was evident in 6 of 9 cases.

In addition, sera from a myositis cohort (n = 129) from the Institute of Rheumatology and the Department of Rheumatology of Charles University in Prague, were examined and compared with sera from HCs (n = 81). Myositis patients fulfilled the diagnostic criteria for definite or probable PM or DM (53, 54) or IBM (55). To characterize FHL1 as an autoantigen more in detail, we analyzed muscle biopsies from 17 IIM patients (PM, n = 13; DM, n = 1; IBM, n = 3) from the Swedish cohort and from 4 HCs by microscopy and/or Western blotting.

For 132 of 141 patients in the Swedish IIM cohort (anti-FHL1+, n = 33; anti-FHL1, n = 99), detailed clinical and laboratory data from patient records at Karolinska University Hospital and from the Web-based SweMyoNet and Euromyositis registries were available. We retrieved and analyzed the following parameters: HLA-DRB1 haplotypes (Supplemental Table 2); descriptive characteristics including sex, diagnosis, demographic data, and disease duration (Supplemental Table 3); clinical muscle features, skin manifestations, extramuscular involvement, and muscle biopsy features (Supplemental Table 4); clinical laboratory measurements (Supplemental Table 5); and autoantibody status (Supplemental Table 6). To estimate the severity of clinical muscle involvement, we developed the following scoring system, considering (a) the overall outcome including the physician’s myositis damage index (MDI) VAS score (established by the International Myositis Assessment and Clinical Studies Group [IMACS]) (56) retrieved from the SweMyoNet registry; (b) the overall disease severity; and (c) the response to treatment: remission without treatment = 0; remission without treatment with an MDI VAS score greater than 2.0 = 0.5; remis-
sion with treatment = 1; low disease activity with treatment = 2; moderate disease activity = 3; refractory, progressive disease, persistent, therapy resistant = 4; an MDI VAS score greater than 5.0 but less than 7.0 = 4.5; and an MDI VAS score greater than 7.0 = 5, respectively. Scoring was done for the last recorded visit by the treating physician who was blinded with regard to the presence of anti-FHL1 autoantibodies.

**Screening of a muscle-specific library.** Putative autoantigens were initially identified using a commercially available muscle cDNA library (Uni-ZAP XR Premade Library; Stratagene, Agilent Technologies). The library was screened using sera from 3 representative patients with adult DM or PM (53, 54), selected according to the following inclusion criteria: patient A represented a classical case of DM; patient B was representative of a diagnosis of DM with an associated malignancy, since patients with paraneoplastic malignancies often develop autoantibodies (57, 58); and patient C was selected because he was considered to have typical PM and had anti-Jo-1 antibodies. Anti-Jo-1 autoantibody positivity was used as a criterion to support the accuracy of PM diagnosis, which should be clearly distinct from a non-inflammatory myopathy. In addition, the presence of this well-known myositis-specific autoantibody was used as an internal control for the cDNA library screening methodology. IBM was not considered in the initial screen, as the role of the immune system in the pathogenesis of IBM is still debatable, and the pathology of this IIM subtype is characterized by a complex interplay of inflammatory and degenerative mechanisms (59, 60). After 4 immunoscreenings using sera from the 3 selected patients, clones were isolated and subjected to PCR amplification as well as DNA sequencing and basic local alignment search tool (BLAST) searches of the Human Genome database (http://www.ncbi.nlm.nih.gov/BLAST/).

**Cloning and expression of recombinant proteins.** Human FHL1 coding DNA sequence (CDS) was amplified from the human FHL1 cDNA ORF clone (transcript variant 2; NM_001449; OriGene) introducing EcoRI (5’-CAACAAGAATTCTAGGGGAGAATTTGACTG-3’) and SalI (5’-CAACAGTCGACTTACAGCTTTTGGCAGCAG-3’) restriction sites and ligated into the multiple cloning site of the pTNT vector (Promega). Using the pTNT vector, the FHL1 ORF was subcloned into either pMAL-cRI (New England BioLabs) or pET-28a (Novogen) expression vectors and proteins with an MaBP tag and a His tag, respectively, were expressed in BL21 E. coli cells. WT MaBP was used as a control. Full-length proteins were purified on amylose columns (for MaBP fusion proteins; New England BioLabs) and Ni-NTA columns (for His-tagged proteins; Pierce, Thermo Fisher Scientific), respectively, according to the manufacturers’ instructions. In some experiments, a commercially available recombinant FHL1 protein (OriGene, transcript variant 2, GenBank accession number NM_001449) was used.

**ELISA for detection of anti-FHL1 antibodies.** ELISA was performed as previously described (61). Briefly, 96-well MaxiSorb plates (Nunc) were coated with 1 μg recombinant FHL1-MaBP or His-tagged FHL1 full-length protein per well diluted in carbonate buffer, pH 9.6, overnight at 4°C. Human sera were measured at a dilution of 1:500; mouse sera were diluted at 1:1,000. Absorbance was measured at 405 nm (A405). For ELISAs with the FHL1-MaBP fusion protein, all sera were tested for reactivity to MaBP alone. In general, the OD values for MaBP-only ELISAs were less than 0.2. Absorbance obtained from FHL1-MaBP ELISAs was normalized to reactivity to MaBP alone by subtracting MaBP-A405 from FHL1-MaBP-A405. Dilutational linearity was ensured by performing serial dilution ELISAs in 1:2 dilution steps. A cutoff value discriminating between anti-FHL1+ and anti-FHL1− patients was defined as the mean Aopt + 2 times the SD of the HC value. For representative patients, longitudinal serum samples were measured. All samples were measured in duplicate, and anti-FHL1+ and anti-FHL1− sera measurements on every plate ensured functionality of the assay.

**Immunoblot analysis.** Immunoblotting was performed with a monoclonal anti-FHL1 antibody (catalog ab76912; Abcam), mouse anti-GAPDH mAb (catalog 398600; Invitrogen), or rabbit anti-GAPDH mAb (catalog 14C10; Cell Signaling Technology), followed by incubation with HRP-coupled anti-mouse (Dako) or anti-rabbit (Dako) secondary antibodies. In some experiments, patient sera were used as primary antibody sources, followed by incubation with HRP-coupled anti-human IgG (Dako). Individual bands were visualized with ECL (GE Healthcare). Quantification was done using Quantity One 1-D Analysis software (Bio-Rad).

**Histopathological examination.** H&E- and Gomori trichrome-stained muscle biopsy sections from 20 anti-FHL1+ patients and 13 sex-, age-, and diagnosis-matched (PM, DM, and IBM) anti-FHL1− patients were available in the muscle pathology repository at the Neuromuscular unit of Karolinska University Hospital and were assessed by an experienced muscle pathologist. Scoring was done blindly with regard to the status of anti-FHL1 autoantibody positivity. Characteristics examined included muscle fiber atrophy, fibrosis, necrosis/degeneration, regeneration, presence of inflammatory infiltrates, internal nuclei, variation of fiber size, and rimmed vacuoles. Overall histopathological severity was scored using a VAS system (0–10 cm) (31).

**Immunofluorescence and confocal microscopy.** Muscle biopsies were frozen in isopentane prechilled in liquid nitrogen, sectioned into 7-μm sections, formalin fixed, and stored at −70°C until processing. Formalin-fixed muscle tissue sections were permeabilized with 0.1% saponin and stained with monoclonal mouse anti-human FHL1 antibody (dilution 1:200; catalog ab76912; Abcam), followed by Alexa Fluor 594–conjugated anti-mouse antibody (Invitrogen). Moreover, unfixed healthy human muscle tissue was stained with sera from anti-FHL1+ and anti-FHL1− patients as well as with sera from HCs (dilution 1:50), followed by incubation with DyLight 594–conjugated donkey-anti-human IgG antibody (Pierce, Thermo Scientific). In some experiments, the positive staining using either commercial anti-FHL1 or anti-FHL1+ human serum was blocked by preincubation with recombinant FHL1-MaBP protein overnight at 4°C. In addition, sections were incubated with rabbit polyclonal anti-laminin, followed by Alexa Fluor 488–conjugated anti-rabbit antibody (Invitrogen). Nuclei were counterstained with DAPI (Roche), and sections were mounted in Fluoromount-G (SouthernBiotech). Images were acquired using a Leica TCS SF5, and acquisition was performed using a ×40 oil-immersion objective. A z-dimension series was taken every 0.2 μm. Images were analyzed with ImageJ software (NIH).

**mRNA expression analysis and qPCR.** For studies with human material, RNA was obtained from muscle biopsies from healthy individuals and myositis patients positive or negative for anti-FHL1 autoantibodies. The RNaseq Fibrous Tissue Mini Kit (Qiagen) was used for RNA extraction. cDNA synthesis was performed with an iScript cDNA synthesis kit (Bio-Rad) following the manufacturer’s protocol. Predesigned and custom TaqMan assays from Life Technologies were used to interrogate the transcript expression levels of 3 well-established splice isoforms of FHL1 (reviewed in ref. 20), as represented by...
their NCBI Reference Sequence (RefSeq) accession numbers: FHLIA, NM_001449.4 (full-length); FHLIB, NM_001159702.2; and FHLIC, NM_001159703.1. Detection of the FHLIB transcript was performed using the predesign real-time gene expression assay Hs00938359_g1 (Applied Biosystems, Life Technologies), with a probe spanning exons 7–8; the context sequence reporter was 5′-FAM-CTCTCTC-GAGGCCCGGTGGGTATTGAA-NFQ**-3′. Two custom TaqMan assays were designed to evaluate the expression of FHLIA and FHLIB transcripts. For the FHLIA transcript, the context sequence spanning exons 6–8 was 5′-FAM-ACCCCATCAGTTGTTGTA-NFQ**-3′, and for the FHLIC transcript, the probe spanning exons 5–8 was 5′-FAM-AGTG-GCAAACAGGTTTG-NFQ**-3′. The experiment was performed at least in triplicate. Three nontemplate controls were included in each experiment. Expression measurements were made using the ΔΔct relative quantification method (ΔΔct) with QuantStudio6 and the 7 Flex Real-Time PCR System and ExpressionSuite Software, version 1.0.4 (all from Thermo Fisher Scientific). The ZNF592 gene was used as an endogenous reference control (predesign assay Hs00206029_m1), the ΔΔct of which was subtracted from each individual measurement. The mean ΔΔct values for controls were used as a calibrator.

For the animal experiment, cDNA was prepared from hind-limb muscle tissue using the Applied Biosystems High-Capacity cDNA Reverse Transcription Kit (Life Technologies; catalog 43-688-14). Total RNA (800 ng) was treated with DNase and reverse transcribed. cDNA (40 ng) was used per 10 μl qPCR reaction. The following assays were selected from the Life Technologies TaqMan repository: Cd4 (Mm00442754_m1); Cd8a (Mm01188922_m1); Gzmb (Mm00442834_m1); and Prf1 (Mm00812512_m1).

Cleavage assays of muscle lysates. Cultured skeletal muscle cells were lysed in 10 mM HEPES, 2 mM EDTA, 1% NP-40 including leupeptin, antipain, pepstatin A, and phenylmethylsulfonyl fluoride (PMSF), and human recombinant granzyme B (all from Enzo Life Sciences) was used in different concentrations for 1.5 hours at 37°C. As indicated in Figure 5B, 5 mM DTT (Sigma-Aldrich), 500 nM z-Vad-FMK, or 500 nM z-DEV-D-FMK (both from BD Pharmingen) was added. In some experiments, 100 ng recombinant protein was used as a substrate. The reaction was loaded onto an SDS-PAGE gel and blotted onto a nitrocellulose membrane. Detection was done with a mouse monoclonal anti-FHL1 antibody (ab76912; Abcam, binding to the N-terminus) or a mouse polyclonal anti-FHL1 (ab29397; Abcam, binding to the C-terminus). The granzyme B cleavage site in FHL1 was confirmed by cloning FHL1 in pTNT plasmid (Promega) and mutating aspartic acid (D) at amino acid position 50 to alanine (A) using site-directed mutagenesis (Agilent Technologies). Primers used for mutagenesis PCR were a149c antisense (5′-CACCTCTTTGAGGCCCGACCGATGGG-3′) and a149c sense (5′-CCCCATCCGGTGGCGGCCCTCAAGGAAGTG-3′). WT and mutated protein were expressed by in vitro transcription/translation (IVTT) (Promega), cleaved with granzyme B, and analyzed by immunoblotting.

HLA genotyping. HLA genotyping was performed using sequence-specific primer PCR (SSP-PCR) (DR low-resolution kit; Olerup SSP), and the PCR products were loaded onto 2% agarose gels for electrophoresis. An interpretation table was used to determine the specific genotype according to the manufacturer’s recommendations (62).

Mass-spectrometric analysis. Bands identified by Western blotting as containing FHL1 were excised from a Coomassie-stained gel (SDS-PAGE). The bands were reduced, alkylated, and digested by trypsin using standard protocols (63). After extraction and desalting using ziptips (Merck Millipore), the peptides were analyzed using on-line nanoflow liquid chromatography, with a C18 reverse-phase column coupled to an LTQ Orbitrap Velos ETD mass spectrometer (Thermo Fisher Scientific). Mass lists were extracted from the raw data using Raw2MGF (64) and searched against the human complete proteome database (2013/14) using the Mascot search engine, v2.4.1 (Matrix Science Ltd.). The following parameters were used for the database search: tryptic digestion (maximum of 2 misscleavages); carbamidem- lation (C) as a fixed modification; oxidation (M), pyroglutamate (Q) as the variable; 10 ppm as the precursor tolerance; and 0.25 Da as the fragment tolerance. MudPIT scoring was used to evaluate the results.

Immunoassays of HT mice. The mouse model of myositis used, including genotyping of the mice, was described previously (35). Briefly, the model uses a tet-off-driven expression of the H-2Kb MHC class I molecule (H gene). Doxycycline was withdrawn from the water at 5 weeks of age to induce expression of MHC class I. To study the effect of FHL1 on development of myositis, female HT (n = 8) and age-matched H mice (n = 8) were immunized s.c. with 250 μg recombinant FHL1-MaBP fusion protein in CFA. For additional controls, age-matched female HT (n = 8) and H mice (n = 8) were immunized with recombinant MaBP in CFA. Two weeks after immunization, mice received a booster consisting of 125 μg FHL1 or MaBP in incomplete Freund’s adjuvant (IFA). Blood was collected routinely at 2, 6, and 10 weeks after immunization and at the time of euthanization. Nine weeks after immunization, BW was determined and grip strength for both forelimbs and hind limbs was assessed using a grip strength meter as described elsewhere (65). Sixteen weeks after immunization, mice were euthanized. Survival is shown using a Kaplan Meier survival plot (Figure 6E). To analyze muscle injury, IgM staining was performed as described previously (66).

Statistics. The significance of differences in the ELISAs, clinical outcome scores, histopathology scores, as well as grip strength and weight measurements in the animal studies were calculated by Mann-Whitney U tests. The significance of differences between anti-FHL- and anti-FHL+ patients was calculated by the Wilcoxon rank-sum test for continuous variables and by Pearson’s χ2 or Fischer’s exact test for categorical variables. Logistic regression analysis was used for assessment of the probability of having anti-FHL1 autoantibodies for different categories of patients. Stata (StatCorp) or GraphPad Prism 6.0 (GraphPad Software) were used for data management and statistical analyses. P values of 0.05 or less were considered statistically significant.

Study approval. Collection of serum and biopsies from IIM patients as well as serum from patients with other autoimmune diseases was approved by the local ethics committee of Karolinska Institutet. Collection of serum from IIM patients from the Czech Republic was approved by the Institute of Rheumatology in Prague. All patients provided informed consent before their participation in this study. All handling and experimentation with mice was approved by the IACUC of the Children’s National Medical Center in Washington, DC.

Author contributions
IA designed the study, conducted and analyzed the experiments, and wrote the manuscript. CW contributed to study design and, with ÅH, conducted muscle cDNA library experiments and initial ELISAs. AT performed statistical analysis of clinical data and edited the manuscript. KN, KT, AP, and WC designed and conducted the
animal study and edited the manuscript. FA designed the granzyme B experiments and edited the manuscript. LMDG designed and performed the qPCRs for the different FHL1 isoforms. MB was the statistician and IN the pathologist for the study. KC and JH provided scientific input and edited the manuscript. KJ and AW contributed to clinical data abstraction for the Swedish cohort. AJY and RAZ conducted the mass spectrometric experiments. OD provided samples and clinical data from patients with NMD. O Krystufkova and JV provided patient samples and clinical data for the Czech cohort and edited the manuscript. NL conducted in vitro experiments. MWH contributed to study design and provided scientific input. LP contributed to study design and analyzed HLA associations. O Kämpe contributed to study design and provided scientific input. IEL designed the study and edited the manuscript.

Acknowledgments

We thank Elisabet Svennungsson and Annika Nordin for providing us with patient sera, Eva Jemseby for careful handling of the serum bank, Eva Lindroos and Barbro Larsson for their excellent technical assistance, nurse Christina Ottosson for her excellent patient care, Maryam Dastmalchi for collecting data for the myositis registries, Megan K. Herbert for providing data on cNLA reactivity in our patient cohort, and Lars Klareskog and Vivianne Malmström for their critical reading of the manuscript. This work was supported by grants from the Swedish Research Council, the Torsten and Ragnar Söderberg Foundations, the Karolinska Institutet, the Börje Dahlin Foundation, the Swedish Rheumatism Association, the King Gustaf V 80-year Foundation, the regional agreement between Stockholm County Council and Karolinska Institutet on medical training and clinical research (ALF), and the Swedish Strategic Foundation (PRIMI).

Address correspondence to: Inka Albrecht or Ingrid E. Lundberg, Karolinska Institutet, Department of Medicine, Rheumatology Unit, Karolinska Hospital Solna, SE 171 87 Stockholm, Sweden. Phone: 46.85.177.0310; E-mail: inka.albrecht@ki.se (I. Albrecht). Phone: 46.85.177.6087; E-mail: ingrid.lundberg@ki.se (I.E. Lundberg).


